These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18262853)

  • 1. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
    Klein MB; Cooper C; Brouillette MJ; Sheehan NL; Benkelfat C; Annable L; Weston F; Kraus D; Singer J;
    Contemp Clin Trials; 2008 Jul; 29(4):617-30. PubMed ID: 18262853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial.
    Klein MB; Lee T; Brouillette MJ; Sheehan NL; Walmsley S; Wong DK; Conway B; Hull M; Cooper C; Haidar S; Vezina S; Annable L; Young S; Zubyk W; Singer J
    HIV Clin Trials; 2014; 15(4):161-75. PubMed ID: 25143025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
    Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
    Morasco BJ; Rifai MA; Loftis JM; Indest DW; Moles JK; Hauser P
    J Affect Disord; 2007 Nov; 103(1-3):83-90. PubMed ID: 17292481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
    Kraus MR; Schäfer A; Schöttker K; Keicher C; Weissbrich B; Hofbauer I; Scheurlen M
    Gut; 2008 Apr; 57(4):531-6. PubMed ID: 18079286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
    Diez-Quevedo C; Masnou H; Planas R; Castellví P; Giménez D; Morillas RM; Martín-Santos R; Navinés R; Solà R; Giner P; Ardèvol M; Costa J; Diago M; Pretel J
    J Clin Psychiatry; 2011 Apr; 72(4):522-8. PubMed ID: 21034680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
    Raison CL; Borisov AS; Broadwell SD; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
    J Clin Psychiatry; 2005 Jan; 66(1):41-8. PubMed ID: 15669887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hepatitis C in HIV infected and other immunocompromised individuals.
    Seth AK
    Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
    Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
    Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
    J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
    Schaefer M; Schwaiger M; Garkisch AS; Pich M; Hinzpeter A; Uebelhack R; Heinz A; van Boemmel F; Berg T
    J Hepatol; 2005 Jun; 42(6):793-8. PubMed ID: 15885349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
    Maor Y; Schapiro JM; Bashari D; Lurie Y; Safadi R; Segol O; Paritsky M; Rachlis Z; Avidan B; Bar-Meir S; Martinowitz U
    Haemophilia; 2008 Mar; 14(2):336-42. PubMed ID: 18205802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
    Annemans L; Warie H; Nechelput M; Peraux B
    Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.